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NeurodegenerationInsulin-like growth factor-II (IGF-II) is a naturally occurring peptide that exerts known pleiotropic effects ranging
frommetabolic modulation to cellular development, growth and survival. IGF-II triggers its actions by binding to
and activating IGF (IGF-I and IGF-II) receptors. In this study, we assessed the neuroprotective effect of IGF-II on
corticosterone-induced oxidative damage in adult cortical neuronal cultures and the role of IGF-II receptors
in this effect. We provide evidence that treatment with IGF-II alleviates the glucocorticoid-induced toxicity to
neuronal cultures, and this neuroprotective effect occurred due to a decrease in reactive oxygen species (ROS)
production and a return of the antioxidant status to normal levels. IGF-II acts via not only the regulation of
synthesis and/or activity of antioxidant enzymes, especially manganese superoxide dismutase, but also the
restoration of mitochondrial cytochrome c oxidase activity and mitochondrial membrane potential. Although
the antioxidant effect of IGF-I receptor activation has beenwidely reported, the involvement of the IGF-II receptor
in these processes has not been clearly deﬁned. The present report is the ﬁrst evidence describing the involve-
ment of IGF-II receptors in redox homeostasis. IGF-II may therefore contribute to the mechanisms of neuropro-
tection by acting as an antioxidant, reducing the neurodegeneration induced by oxidative insults. These results
open the ﬁeld to new pharmacological approaches to the treatment of diseases involving imbalanced redox
homeostasis. In this study, we demonstrated that the antioxidant effect of IGF-II is at least partially mediated
by IGF-II receptors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Insulin-like growth factors (IGF-I and IGF-II) are naturally occurring
peptides with known pleiotropic effects as growth factors. These endo-
crine, paracrine and autocrine effects range from metabolism to devel-
opment, including neurogenesis and cellular maturation, proliferation,
survival and growth. The majority of its actions are mediated primarily
by insulin receptors, IGF-I receptors (IGF-IRs) and, although less under-
stood, IGF-II/mannose-6-phosphate receptors (IGF-IIRs) [1]. Further-
more, several IGF-binding proteins (IGFBPs) may enhance or abrogate
the effects of IGF [2]. IGF-II, a 67 amino acid peptide hormone that
displays extensive interspecies homology [3,4], is synthesised at high
levels during embryonic development. However, in adults, there is aave read and approved theﬁnal
4 952131650.decrease in its synthesis, although IGF-II remains the most abundant
insulin-like peptide in the adult brain, primarily expressed in the cho-
roid plexus, the leptomeninges and the hypothalamus [5]. IGF-IIR is
also the most abundant insulin-like receptor in the adult brain. The
physiological actions of IGF-II in adults are not well deﬁned, although
some studies have demonstrated an association of these peptides with
cognitive processes, such as memory [6], and neuroprotection against
neurodegenerative excitotoxic injuries [7]. In a previous ex-vivo study,
the authors demonstrated the neuroprotective effects of IGFs (I and II)
as antioxidants via the regulation of intracellular calcium levels and
the restoration of mitochondrial membrane potential (MMP) [7,8].
Moreover, a previous report by our group indicated that administration
of lowdoses of IGF-II to old animals (24month-oldWistar rats) induced
neuroprotective effects and decreased the levels of oxidative stress
markers in the hippocampus and the cortex. These effectswere attribut-
ed to IGF-II, as IGF-I plasma levels remained unchanged in these exper-
imental animals [9].
However, glucocorticoids, such as corticosterone (CORT), increase
free-radical generation and impair mitochondrial function [10,11].
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the GSH/GSSG ratio, the enzyme activities of complexes I and IV and
MMP in mitochondria isolated from mice [12]. In neuronal cultures,
similar alterations in mitochondrial function have also been reported
[13,14]. Furthermore, mitochondrial dysfunction impairs energy pro-
duction [12] and calcium storage capacity and increases ROS produc-
tion, leading to oxidative damage [13,14], reducing the neuronal
survival rate [10] and contributing to an enhanced neurotoxicity of
kainate. In fact, mitochondrial dysfunction has been reported as a puta-
tive mechanism underlying the pathophysiology of some neurological
and neuropsychiatric disorders [12,15,16]. In this sense, prolonged
exposure to high levels of glucocorticoids, such as those observed
during stress responses, impairs both neuroplasticity and cognition
and can facilitate the neuronal damage induced by several insults, in-
cluding ischemic stroke and oxidative stress, increasing the susceptibil-
ity to develop neuropsychiatric and neurodegenerative disorders [15,
17].
Recently, IGF-II has been linked to neuropsychiatric conditions asso-
ciated with high glucocorticoid levels, such as depression. Along these
lines, decreased mRNA levels of IGF-II have been reported in animal
models of stress [18,19] and endogenous depression [18]. Conversely,
pharmacological treatments that exhibit antidepressant-like properties
(desipramine anddicholine succinate) induced the up-regulation of Igf2
gene expression [19,20]. These recent studies strongly suggest putative
roles of IGF-II in the development of and recovery from glucocorticoid-
and stress-related disorders.
Altogether, in the present study, we hypothesised that IGF-II,
primarily via the IGF-IIR, protects cortical neurons against neurotoxic
oxidative damage associated with increased brain corticosteroid levels.
This study may contribute to the development of a new therapeutic
strategy in which IGF-II may be targeted for the treatment of neurode-
generative and neuropsychiatric disorders. To achieve this goal,
we used an “ex vivo” model in which inhibitors of IGF-II and the IGF
receptors (IGFRs) I and II were administered to adult cortical neuronal
cultures under CORT-induced oxidative stress conditions. Under these
experimental conditions, wemeasured several oxidative stress parame-
ters, particularly ROS production in whole cells and total antioxidant
status (TAS), lipid hydroperoxide (LOOH) levels, superoxide dismutase
(SOD) and glutathione peroxidase (GPX) antioxidant activity and PKC
expression in cell homogenates. In addition, mitochondrial membrane
potential (MMP) and cytochrome c oxidase (COX) activity were also
measured to evaluate mitochondrial function.
2. Material and methods
2.1. Preparation of cortical neuronal cultures
Cultures of cortical neurons from adult ratswere prepared according
to a previously published procedure with minor modiﬁcations [21].
After animal decapitation, the cortexwas removed, and slices of approx-
imately 0.5 mm were transferred to tubes containing Hibernate™-A/
B27™ supplement (B27) (Life technologies, Spain) and papain at the
appropriate concentration and incubated for 30 min in a 30 °C water
bath with gentle shaking. Then, the slices were triturated 10 × 3
times. The cells obtained from the sections were suspended in OptiPrep
gradient medium (SIGMA, Spain) and centrifuged at 800 ×g for 15min.
The fractions containing neurons were collected, suspended in Hiber-
nate™-A/B27 and centrifuged twice at 200 ×g for 2 min. The pellets
were then resuspended in growth culture medium (Neurobasal™-A/
B27 containing glutamine, FGF2 and penicillin/streptomycin, Life
Technologies, Spain). For cell culture, 6- and 24-well plates were pre-
coated with 100 μg/mL of poly-D-lysine. For immunohistochemical
studies, glass coverslips (12 mm diameter) were pretreated with
polyethylenimine (1/500 v/v in ddH2O) followed by 2.5% FBS. Approxi-
mately 500,000 (6-well plates) or 125,000 (24-well plates) cells were
seeded. The neurons were then incubated at 37 °C in 5% CO2, and after1 h, the wells were rinsed twice with Neurobasal™-A and ﬁlled with
growth culture medium. The media were replaced with fresh media
(half volume) every 4 days. The experiments were performed after
12 days of growth.
This model has some strengths and limitations. The model does not
include all factors that can be found in a complete living organism. This
could be considered as a negative, but at the same time, it could be
regarded as an important advantage. For instance, in the present
study,we used serum-freemedia, and therefore those factors associated
with the IGF system, such as IGFBPs [22,23] and other proteases, such as
Htra1 [19], that could inﬂuence the interaction of IGF with its receptors
or modulate the bioavailability of IGF are not present. The absence of
these factors in the cultures allows us to more accurately interpret the
results.
All experimental procedures were performed in accordance with
European animal research laws (European Communities Council Direc-
tive 2010/63/EU) and the Spanish National Guidelines for Animal
Experimentation (Real Decreto 1201/2005 and Ley 32/2007). All animal
procedures were approved by the Institutional Animal Care and Use
Committee of Malaga University.
2.2. Cellular treatment
In order to avoid the antioxidant properties of B27, this supplement
was removed from the culture media, and the cells were maintained
under this condition for 24 h before the experiments were performed.
The cell cultures were exposed to: 10 μM CORT; 100 ng/mL IGF-II;
10 μM CORT in the presence of 100 ng/mL IGF-II; 10 μM CORT and
100 ng/mL IGF-II in the presence of 20 ng/μL IGF-I analogue (JB1,
Bachem, Switzerland) or 5 ng/μL anti-IGF-IIR (R&D Systems, USA) and
10 μM CORT in the presence of 100 ng/mL IGF-II with 20 ng/μL JB1
and 5 ng/μL anti-IGF-IIR. The incubation time was 2 h, and the temper-
ature was 37 °C. All of the measurements were performed immediately
after treatment, except for the measurement of neurodegeneration,
which was evaluated 24 h after cell treatment (pre-rinsed with B27-
free medium).
2.3. Cortical cell viability
Viability was determined by quantifying the release of the intracel-
lular enzyme lactate dehydrogenase (LDH, EC 1.1.1.27) [24]. The LDH
levels weremeasured in cell-free culture supernatants using a commer-
cial spectrophotometric assay kit (Randox Laboratories Ltd., UK)
adapted to a CobasMira Autoanalyser (ABXDiagnostics, France). The re-
sults are expressed as the percentage of LDH released into the medium
relative to total LDH (medium and cells lysed using Triton X™-100).
2.4. Preparation of homogenised cells from cortical neuronal cultures
The cells were suspended in buffer containing 10mMHEPES, pH 7.4,
10 mM KCl, a protease inhibitor cocktail (Roche, Spain) and phospha-
tase inhibitors (SIGMA, Spain), incubated at 0 °C for 20 min and
homogenised in the presence of 0.01% digitonin. The protein concentra-
tions were determined via quantiﬁcation of UV 280 nm absorbance
using a Nanodrop™ (Thermo Scientiﬁc NanoDrop Products, USA). COX
activity, LOOH levels and TAS (see below) were determined in the
homogenates [25]. Western blot analyses were performed using the
same homogenates without incubation in digitonin.
2.5. Determination of intracellular levels of ROS
Cellular ROS production was estimated by measuring O2−• produc-
tion via ﬂow cytometry using a dihydroethidium (DH2) probe accord-
ing to a previously published procedure [25,26]. Prior to the end of the
incubation period, the cells were labelled with 5 μM DH2 in B27-free
medium for 1 h at 37 °C. The cells were then washed and immediately
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an EPICSXL ﬂow cytometer (Beckman-Coulter, USA). Ten thousand
events (cells) were recorded and evaluated usingWINMDI 2.8 software
(http://www.cyto.purdue.edu/ﬂowcyt/software/Winmdi.htm). Incuba-
tion in 100 μM Menadione for 2 h was used as an oxidative stress
control.
2.6. Markers of oxidative stress
Oxidative stress was evaluated by measuring the cellular level
of lipid peroxidation, i.e., LOOH and the TAS in cell homogenates.
The LOOH levels were regarded as the extent of lipid peroxidation, as
LOOH comprises the intermediates of ROS-induced oxidation of phos-
pholipids, glycolipids and cholesterol [27]. LOOH was measured using
the FOX2 method [28] and adapted to a Cobas Mira Autoanalyser [29,
30]. The LOOH level was calculated relative to a hydrogen peroxide
standard curve. The LOOH levels were expressed as nmol/mg of protein.
The TAS, i.e., the total enzymatic and nonenzymatic antioxidant capaci-
ty, was evaluated in cells using a commercial TAS kit (Randox Laborato-
ries Ltd., UK) adapted to a Cobas Mira Autoanalyser that measures the
formation of the radical cation ABTS•+™ at 600 nm using ABTS™ in
the presence of a peroxidase (metmyoglobin) and H2O2 [25,31]. The
ﬁnal values were expressed as μmol/mg of protein.
2.7. Electrophoresis and Western blot
The samples were resuspended in (5X) polyacrylamide gel electro-
phoresis (SDS-PAGE) loading buffer and boiled at 100 °C for 3 min
using a thermo-block. The samples were then loaded (15 μg of pro-
tein/well) on a 12% polyacrylamide gel and subjected to a constant cur-
rent of 130 V. The transfer was performed using a semi-dry transfer
device (Multiphor II™, GE Healthcare Life Sciences, Spain) on graphite
plates to a nitrocellulosemembranewith a pore size of 0.45 μm(current
intensity: 0.8 mA/cm2 for 45 min). After blocking, the membrane was
incubated in various primary antibodies (produced in rabbit) at differ-
ent dilutions (anti-GPX1/2, -pPKC and -SOD-2, 1:200, and anti-β-actin,
1:500; Santa Cruz Biotechnology, Spain) for 12 h at 4 °C, followed by in-
cubation for 1 h in the anti-rabbit IgG alkaline phosphatase conjugated
secondary antibody (Sigma, Spain) at a 1:10,000 dilution. The ﬁnal
colour reaction was developed using nitro blue tetrazolium/5-bromo-
4-chloro-3-indolyl phosphate (NBT/BCIP). The Western blots were
digitised using a ﬂatbed scanner (HP Scanjet 5500c, Hewlett-Packard,
Spain) and analysed using ImageJ software (US National Institute of
Health; http://imagej.nih.gov/ij/).
2.8. Measurement of mitochondrial function markers
Asmitochondrial functionmarkers, we choseMMPand COXactivity.
MMP was evaluated using the lipophilic cationic probe 5,5,6′,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbo-cyanine iodide
(JC-1) according to a previously described procedure [32,33]. JC-1 is a
lipophilic carbocyanine that exists in a monomeric form and accumu-
lates in mitochondria. In the presence of a high MMP, JC-1 reversibly
forms aggregates that, after excitation at 488 nm, ﬂuoresce in the
orange/red channel (FL2—590 nm). A collapse of the MMP provokes a
decrease in the number of JC-1 aggregates (see cells incubated in
valinomycin) and a subsequent increase in monomers that ﬂuoresce
in the green channel (FL1—525 nm). This phenomenon is detected as
a decrease in the orange/red ﬂuorescence and/or an increase in
the green ﬂuorescence. The distribution of monomeric and aggregated
JC-1was determined via ﬂuorometry to quantify theMMP and via ﬂuo-
rescence microscopy to analyse the intracellular heterogeneity of the
mitochondria. The cells were incubated in 1 μg/mL JC-1 in B27-free
medium for 20 min at 37 °C. Then, the cells were rinsed twice with
B27-free medium and observed under an inverted ﬂuorescence micro-
scope (Leica DMIL with a 50-W HBO Mercury Short-Arc Lamp) usingFITC (490/515) and TRITC (550/580) ﬁlter sets. Images were captured
using a cooled Nikon Digital Sight DS-5Mc camera (Nikon Europe B.V.,
Spain). The images were acquired at 20X magniﬁcation and processed
using ImageJ software. The ﬂuorescence intensity was determined
using a FLUOstar Galaxy spectrophotometer (BMG, Lab Technologies,
Germany) at 490/530 nm (for JC-1 monomers) and 525/590 nm
(for JC-1 aggregates). The fraction of aggregated JC-1 was quantiﬁed
as FL2 average/(FL2 average + FL1 average), which provided the most
reproducible estimate of MMP. This ratio was found to be insensitive
to a 10-fold variation in the JC-1 concentration. To completely deplete
the MMP, the potassium ionophore valinomycin (1 μM) was used as a
control.
COX (EC 1.9.3.1) activity in cell homogenates was assessed using a
COX assay kit (Sigma, Spain) adapted to a Cobas Mira Autoanalyser
[34]. One unit was deﬁned as the oxidation of 1.0 μmol of
ferrocytochrome c per minute at pH 7.0 and 37 °C.
2.9. Assessment of neurodegeneration in cell culture
Neurodegeneration of the cultured cortical neurons was measured
using Fluoro-Jade B™ (FJ) dye according to a previously published pro-
cedure [35]. The cell culture plates were ﬁxed using cold ethanol
(−20 °C) for 30 min and washed three times with distilled water. The
cells were treated with the dye (ﬁnal concentration of 0.0004% FJ in
0.1% acetic acid) and gently shaken for 30 min in the dark at RT and
then washed twice with distilled water. Finally, the ﬂuorescence inten-
sitywas determined using a FLUOstar Galaxy spectrophotometer (BMG,
Lab Technologies, Germany) at 485/530 nm.
2.10. Double immunocytochemical staining of cortical neurons
Fixation was accomplished by treating the plate with methanol pre-
viously chilled to −20 °C and incubating at −20 °C for 20 min. The
wells were washed with PBS, and the coverslips were removed and in-
cubated in a primary antibody solution containing the following: 1:15
goat anti-IGF-IIR (R&D Systems, USA) and 1:250 rabbit anti-NeuN
(Millipore, Spain) antibodies in PBS, 3% BSA and 0.02% sodium azide at
4 °C overnight. Then, the coverslipswere incubated in a ﬂuorescent sec-
ondary antibody solution containing a mixture of 1:500 Alexa Fluor™
488 anti-goat (Life Technologies, Spain) and 1:500 Alexa Fluor™ 568
anti-rabbit (Life Technologies, Spain) in PBS for 1 h at room temperature
in the dark. The coverslips weremounted using Fluoromount™ (Sigma,
Spain). Images were acquired using an Olympus BX51 epiﬂuorescence
microscope at 40X magniﬁcation and processed using ImageJ software
(US National Institute of Health; http://rsbweb.nih.gov/ij/).
2.11. Statistical analysis
Statistical differences were determined using one-way ANOVA.
Pairwise comparisons were performed using a post hoc Bonferroni t
test. Statistical signiﬁcance was considered to be p b 0.05. For data in
which the measured units are arbitrary, the respective values represent
the percentage relative to the control value.
3. Results
3.1. ROS production in cell cultures
To evaluate the protective effect of IGF-II on neurons we used a
model of adult rat cortical neuronal cultures incubated in a pathophys-
iological concentration of CORT (10 μM).We investigated the intracellu-
lar production of ROS, the antioxidant effect of a low concentration of
IGF-II and the role of IGF-IIR in these effects.
Under pathophysiological conditions, such as severe stress, plasma
CORT levels in rats increase up to 1–2 μM [12,23,36]. In vitro, concentra-
tions of CORT between 1 and 10 μM or even higher (50 μM) are
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intentionally treated cortical neurons with a high dose of CORT
(10 μM) to attain a clear increase in ROSproduction (Fig. 1a) in 2 hwith-
out notable necrosis or cytotoxicity, as shown in the survival curve
(Fig. 1b).
The low concentration of IGF-II was chosen based on the results
of previous experiments [9,39,40] that demonstrated the capacity of
IGF-II to induce neuroprotection by reducing oxidative stress in the cor-
tex and the hippocampus of aged rats. In addition, in “in vivo” studies,
similar concentrations of endogenous IGF-II were found in damaged
brain tissue; also, such concentrationswere used in further experiments
to investigate the effect of IGF-II on brain function and their ability to
induce neurogenesis and neuroprotection [17,41–43]. In the present
study, we determined the minimal nontoxic IGF-II concentration
based on the survival curve (Fig. 1c).
As IGF-II activates both the IGFRs, I and II, at different afﬁnities [44],
in order to clarify the inﬂuence of each individual subtype in the
ultimate effect, we performed a set of experiments using selective
IGFR inhibitors [6,45].
To assess the inﬂuence of IGFR inhibitors in the absence of IGF-II
from the incubation media, a set of experiments was performed, and
neither AB nor JB1 resulted in any effect on intracellular ROSproduction.
These treatments were excluded from the present study. The control
cells treatedwith IGF-II did not display any difference in ROS production
compared to untreated cells (Fig. 1d).
Treatment with CORT at 10 μM produced an increase in the
ﬂuorescence of DH2 (aROS-superoxide indicator) to a level signiﬁcantly
higher than that of the control (CO) cells (a 40% increase). Addition of
100 ng/mL of IGF-II to the CORT-treated cells restored the ROS levels
to those found in the CO cells (Fig. 2a and b). The addition of speciﬁc
inhibitors of the IGF-IIR (anti-IGF-IIR antibody, AB) or the IGF-IR (JB1,
a potent inhibitor of IGF-I receptor autophosphorylation) did not
alleviate the effect of the low concentration of IGF-II (Fig. 2a and c),Fig. 1. Effect of corticosterone and IGF-II on viability and ROS production in adult neuronal cell
bation of adult rat cortical neuronal cells with 10 μMCORT. The free radical generatormenadion
CORT (c) and effect on adult neuronal cultures using the LDH release into the medium as an in
histogram showing the effect of 100 ng/mL IGF-II on ROS production in control adult neurona
± SEM. *p b 0.05, **p b 0.01 compared with non-treated cells.but co-incubation of both inhibitors completely abolished the antioxi-
dant effect of IGF-II (Fig. 2a and d).
3.2. Oxidative stress cellular markers
In agreementwith the above ﬁndings, the TAS, i.e. the fraction of the
antioxidant pool available for further anti-ROS activity, was signiﬁcantly
lower in cortical neurons incubated in CORT compared to the CO cells.
Addition of the low concentration of IGF-II to the incubation media re-
stored the TAS found in cultures incubated in CORT to that of the CO
cells (Fig. 3a). Co-incubation of the CORT- and IGF-II-treated cells with
JB1 or AB did not reverse the antioxidant effect of IGF-II; although
some effect could be detected after the addition of AB, the decrease in
the protective effect produced by IGF-II did not reach statistical signiﬁ-
cance. Nevertheless, the co-incubation of IGF-II with both inhibitors
fully abolished its antioxidant effect.
The occurrence of oxidative stress and lipid membrane damage by
ROS in cortical neurons was conﬁrmed based on the cellular levels of
lipid hydroperoxides (LOOHs). The results were very similar to those
mentioned above. The cellular concentration of LOOH was signiﬁcantly
higher in CORT-treated neurons than in CO neurons (Fig. 3b). Addition
of the low concentration of IGF-II to the culture medium restored the
LOOH levels to control levels. Individually adding the inhibitor JB1 or
AB to the CORT- and IGF-II-treated cells did not alter the LOOH levels,
but co-incubation of both inhibitors dramatically increased the levels
of LOOH to the same value as that of the CORT-treated cells.
3.3. Expression of antioxidant enzymes
In the present study, we measured the concentrations of enzymes
involved in maintaining the intracellular redox equilibrium. The level
of mitochondrial antioxidant enzyme superoxide dismutase (SOD-2,
MnSOD), which rapidly catalyses the dismutation of superoxide tocultures. (a) Representative histogram showing the increase in ROS production after incu-
e (MEN)was used as control. Survival curve of CORT (b) and IGF-II in the presence of 10 μM
dicator. The maximum LDH release was produced by Triton X™-100. (d). Representative
l cells. Data were combined from 2 to 3 independent experiments and presented as mean
Fig. 2. Effect of IGF-II on ROS production in adult neuronal cortical cells. Adult rat cortical neurons incubated with 10 μM CORT, showed an increase in ROS production as displayed by
DH2 staining; levels of ROS were restored to CO levels by a low concentration of IGF-II. The addition of speciﬁc inhibitors of IGF-IR or IGF-IIR did not reverse the effect of a low concen-
tration of IGF-II but co-incubation with both inhibitors completely abolished its effects. Data were combined from 5 to 6 independent experiments and presented as independent values.
&&&p b 0.001 compared to CO; ***p b 0.001 compared to CORT. (a) Cytoﬂuorimetric analysis of ROS production in adult neuronal cells after incubation with different substances; values in
this panel represent percentage of CO value. Representative histograms showing (b) the effect of IGF-II in ROS production. (c) The effect of IGF-II persists when either IGFR I or II was
inhibited. (d) Restoring ﬂuorescence to CORT levels after co-incubation with both IGFR inhibitors.
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compared to the CO cells (up to 57% less than the CO cells) (Fig. 4a).
Co-incubation of the cells with IGF-II and CORT partially alleviated this
decrease in the MnSOD levels compared to CO cells (up to 30% less
than the CO cells, compared to 57% as shown above) (Fig. 4a). The addi-
tion of the IGFR inhibitor JB1 or AB individually to the CORT- and IGF-II-
treated neurons, did not signiﬁcantly affect the levels of MnSOD com-
pared to the CORT- and IGF-II-treated neurons (21% and 36% less than
the CO cells, respectively). However, co-incubation of both inhibitors
(JB1 and AB) signiﬁcantly decreased the MnSOD levels similar to those
found in the CORT-treated cells (60% less than the CO cells). The expres-
sion of GPX, an enzyme that neutralises H2O2 and LOOH using GSH [46],Fig. 3. Oxidative chemistry biomarkers. Levels of TAS (a) and LOOH (b) after different treatmen
mean ± SEM. &p b 0.05, &&p b 0.01 compared to CO; *p b 0.05, **p b 0.01 compared to CORT.was signiﬁcantly enhanced (70%more than the CO cells) in cortical neu-
rons treated with CORT (Fig. 4b). This considerable increase was
completely alleviated by incubating the cells in the low concentration
of IGF-II. The beneﬁcial effect of IGF-II on the damage induced by
CORT was only partially prevented by incubation in either the inhibitor
JB1 or AB. However, co-incubating the cells with both inhibitors totally
abolished the protective effect of IGF-II.
3.4. Mitochondrial function in neurons
Mitochondria are themajor source of physiological and pathological
cellular ROS. To assess mitochondrial function, we evaluated oxidativet conditions. Data were combined from 3 to 4 independent experiments and presented as
Fig. 4. Expression of antioxidant enzymes GPX and MnSOD. Representative Western blots (upper panels) and quantiﬁcations after normalising with β-actin (lower panels) demonstrate
the IGF-II recovery from the imbalance of the amount of antioxidant enzymes triggered by CORT. (a) Increase in the level of MnSOD after CORT+ IGF-II co-incubation. (b) IGF-II restores
GPX levelsmodiﬁed by CORT. Datawere combined from3 to 4 independent experiments and presented asmean± SEM. &p b 0.05, &&p b 0.01, &&&p b 0.001 compared to CO; *p b 0.05,
**p b 0.01, ***p b 0.001 compared to CORT. Data in graphs represent percentage of CO value.
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activity, which is the rate-limiting step of themitochondrial respiratory
chain [48].
Mitochondria from healthy control cells exhibiting high membrane
potential (which allows JC-1 to spontaneously form aggregates) emit
orange-red ﬂuorescence (Fig. 5c arrows). After incubation in CORT,
the mitochondria become partially depolarised, decreasing JC-1
complex formation and thus emitting yellow-green ﬂuorescence.
Co-incubation of the cells with CORT and IGF-II prevented the damage
induced by CORT alone, which resulted in the recovery of the orange-
red ﬂuorescence. No signiﬁcant changes in the ﬂuorescence were
detected after incubation of the cells in CORT, IGF-II and either JB-1 or
AB compared to the cells treated with CORT and IGF-II. Co-incubation
with both inhibitors together (JB-1 and AB) partially shifted the ﬂuores-
cence to yellow-green, indicating MMP levels similar to those found in
the CORT-treated cells.
Analysis of the JC-1 labelling pattern revealed intracellular heteroge-
neity ofmitochondria, which indicated diversemembrane potential and
spatial localisation (see the insert of Fig. 5c). Again, we detected the dis-
tribution pattern and alterations induced by CORT (e.g. yellow-green
mitochondria near the cell soma; see arrow in Fig. 5c and the insert)
that were not apparent when the cells were co-incubated with IGF-II.
No relevant changes in the mitochondrial ﬂuorescence pattern were
detected upon incubation of the cells in CORT, IGF-II and either JB-1 or
AB, whereas the co-incubation with both inhibitors produced the
same pattern as that of the CORT-treated cells.
Pre-treatment with valinomycin, which dissipates the potassium
gradient and diminishes the MMP, displayed a dramatic effect on the
red ﬂuorescence (Fig. 5c medium panel), which became very faint. In
contrast, valinomycin treatment caused a slight but detectable increase
in the green ﬂuorescence intensity. As a result, the overlay images
displayed the majority of mitochondria exhibiting green ﬂuorescence.
To obtain a more precise quantiﬁcation of the ﬂuorescence intensity
as an indicator of MMP, we measured the JC-1 ﬂuorescence using a
spectroﬂuorometer and calculated the ratio of FL2/(FL1 + FL2), whichreﬂects the average MMP of all mitochondria inside the cells. We
found that after CORT treatment, MMP was signiﬁcantly decreased,
and this ratio was restored to the CO level by treatment with a low con-
centration of IGF-II (Fig. 5a). No changeswere detected upon incubation
in CORT, IGF-II and either JB-1 or AB, whereas co-incubation with both
inhibitors restored the MMP to that of the CORT-treated cells (Fig. 5a).
When we analysed COX activity as a marker of respiratory chain
function, we found that cortical neurons incubated in CORT displayed
a signiﬁcant decrease in the COX activity (Fig. 5b). The COX activity
returned to the CO level when the cells were incubated in a low concen-
tration of IGF-II. When the cells were incubated in CORT in the presence
of IGF-II and the inhibitor JB1, COX activity was slightly increased. How-
ever, incubation of the cells in CORT in the presence of IGF-II and the
inhibitor AB signiﬁcantly increased COX activity. Co-incubation of both
JB1 and AB resulted in a reversion of COX activity to a level near that
of the CORT-treated cells.
3.5. Neurodegeneration
As increased ROS production and mitochondrial dysfunction play
crucial roles in major neurodegenerative disorders, we examined
neuronal degeneration using the polyanionic stain FJ to speciﬁcally
detect neurodegeneration independent of the mode of insult;
this probe is speciﬁc to a late stage of the degenerative process [35]. Ex-
perimentally, ourmodel did not allow us to study prolonged incubation
periods, as adult neuronal cultures require antioxidants (B27™ supple-
ment) in the culture media. Thus, only short periods (24–48 h) in the
absence of antioxidants can be used to avoid spontaneous degeneration
of the neurons.
A large and signiﬁcant increase in the FJ ﬂuorescence intensity of the
CORT-treated cells was detected compared to the CO cells (Fig. 6). Addi-
tion of 100 ng/mL of IGF-II to the culture medium completely alleviated
this increase. The addition of each inhibitor (JB1 or AB) did not exert any
change in the effect of IGF-II, whereas the addition of both inhibitors to-
gether returned the ﬂuorescence level to that of the CORT-treated cells.
Fig. 5.Mitochondrial membrane potential and cytochrome c oxidase activity. (a) Fluorometric analysis of the IGF-II recovery on theMMP decreased by CORT. Data represent the percent-
age of COvalue. (b) IGF-II restores the COX activity decreased byCORT. &p b 0.05, &&p b 0.01, &&&p b 0.001 compared to CO; *pb 0.05, **p b 0.01, ***p b 0.001 compared to CORT. Datawere
combined from 2 to 3 independent experiments and presented as mean ± SEM. Representative images of MMP staining with JC-1 probe after incubation with different substances.
(c) Effect of IGF-II on cells incubated with CORT and the abolishment of this effect in the presence of IGFR blockers. Valinomycin was included as control. Upper and middle (c) panels
show the monomer (green) and aggregate (red) ﬂuorescence, respectively. The lower panels show the overlay of both ﬂuorescences; in this case, the orange/yellow colour denotes
co-localisation of red and green signals. Thus, since the amount of cationic dye taken up by themitochondrion depends on its MMP, at low Δψm the ﬂuorescence emission will bemostly
yellow-green (monomer mainly), whereas at high Δψm it will shift to orange-red (forming aggregate). Detailed distribution of ﬂuorescence is indicated by arrowheads and magniﬁed
image.
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To conﬁrm the presence of the IGF-IIR in the cultures of the analysed
adult cortical neurons, we further performed IGF-IIR/NeuN double
immunostaining experiments. Double immunostaining analysis con-
ﬁrmed the neuronal expression of the IGF-IIR. The cellular distributionof IGF-IIR + immunoreactivity was primarily located in the soma and,
to a lesser extent, in the cellular projections (Fig. 7a).
We also chose to examine PKC activation because this enzyme is
activated by IGF-II, glucocorticoids and ROS [36,49,50]. To assess the ac-
tivation of PKC, we analysed the expression of its phosphorylated form
(pPKC). CORT treatment resulted in an increase of pPKC expression
Fig. 6. Neurodegeneration in adult cortical neuronal cultures. FJ ﬂuorescence
increases after incubation of adult neurons with 10 μM CORT. Co-incubating the cells
with CORT + IGF-II completely reverted this increase. The use of inhibitors (JB1 or AB)
did not exert any change when incubated individually with IGF-II, whereas the use of
both inhibitors together abolished the protective effect developed by IGF-II against the
CORT induced damage. Kainic acid (1 mM) was used as control. Data were combined
from 2 to 3 independent experiments and presented as mean ± SEM of percentage of
CO value. &p b 0.05, &&&p b 0.001 compared to CO; ***p b 0.001 compared to CORT.
Fig. 7. IGF-II receptor expression in neuronal cells andmodulation of PKC activation. (a) The pres
of double ﬂuorescent immunostaining for IGFII-R (Alexa Fluor™ 488) and NeuN, a neuronal ma
heads andmagniﬁed image. (b) IGF-II restores to CO levels the pPKC amount increased by COR
mean ± SEM. &p b 0.05 compared to CO; *p b 0.05, **p b 0.01 compared to CORT. Data after n
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low concentration of IGF-II. Treatment with each inhibitor (JB1 or AB)
did not exert any change in the effect of IGF-II on pPKC expression,
whereas treatment with both inhibitors together re-established the
level of pPKC expression to that of the CORT-treated cells (Fig. 7b).4. Discussion
We and others have recently reported that IGF-II and IGF-I replace-
ment therapy exert neuroprotective antioxidant effects on pathophysi-
ological processes [9,51], such as acute hypoxia, cerebral ischemia
and aging [9,52,53]. For the most part, the effects of IGF are primarily
mediated via the IGF-IR and, although less known, the IGF-IIR [54].
The aim of this study was to determine the inﬂuence of the IGF-IIR on
the antioxidant effects of IGF-II in the brain on CORT-induced oxidative
damage.
The primary outcome of the present study is the ﬁnding that IGF-II
displayed antioxidant effects on neuronal cultures from the adult rat
cortex when exposed to ROS-mediated damage induced by glucocorti-
coids, and this effect is mediated in part by the IGF-IIR. These ﬁndings
are supported by the following experimental results: a) the levels of
ROS, in particular O2−•, produced by incubation of neurons in a high
concentration of CORT were signiﬁcantly higher than those found in
the CO neurons. Moreover, co-treatment of the cells with CORT and aence of IGF-IIRwas conﬁrmed in adult neuronal cell cultures by simple andmerged images
rker (Alexa Fluor™ 568). Detailed distribution of immunoreactivity is indicated by arrow-
T incubation. Data were combined from 2 to 3 independent experiments and presented as
ormalising were presented as percentage of CO value.
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b) TAS, deﬁned as the fraction of the antioxidant pool available for fur-
ther anti-ROS activity, is signiﬁcantly reduced in the neurons incubated
in CORT compared to the CO neurons. Again, co-incubation with IGF-II
alleviated the reduction in TAS; and c) the LOOH level, considered as a
reliable initial biomarker of lipid membrane damage, was signiﬁcantly
higher in CORT-treated cells, and co-treatment with IGF-II completely
abrogated this increase in the LOOH level, returning the LOOH level
near that of the CO cells. Moreover, the detected increase in the LOOH
levels after CORT treatment led to an enhancement in hydroperoxide-
reducing enzyme (GPX) levels, and this increase was inhibited by IGF-
II treatment. Similar effects of IGF-II on these oxidative markers have
also been reported in the aged brain [9].
The present results suggest that the oxidative stress induced by
CORT and the reduction in oxidative damage associated with IGF-II
treatment as performed in our study could be closely associated with
mitochondrial activity. It is well understood that mitochondria are the
major source of physiological and pathological cellular ROS and contrib-
ute to the oxidative damage found in several neuropathological condi-
tions related to enhanced glucocorticoid expression [13]. In our study,
we also reported some changes in mitochondrial antioxidant defence
caused by CORT treatment, leading to the aforementioned oxidative
damage. First, when the cells were incubated in CORT, we detected a de-
crease in the expression of mitochondrial SOD, which rapidly catalyses
O2−•, the predominant species that leads to the formation of other ROS
[55,56]. Co-incubation of IGF-II and CORT signiﬁcantly increased the ex-
pression of the protective enzyme MnSOD and, once again, this effect
was mediated by both IGFR-I and -II. Secondly, in agreement with Lee
et al. [57], we detected decreases in MMP and COX activity, which are
associated with mitochondrial dysfunction, as well as an increase in
ROS production after incubation in CORT. A decrease in the MMP alters
the energy and calciummetabolism of neurons, as suggested by the cel-
lular distribution andmorphology of themitochondria (see the insert of
Fig. 5c).We found that healthymitochondria (emitting orange-redﬂuo-
rescence) appeared to be uniformly distributed inside the cells,whereas
impaired mitochondria (emitting yellow-green ﬂuorescence) returned
to the cell soma, perhaps for destruction or repair [12,58]. IGF-II can
restore the MMP levels not only via its interaction with the IGF-IR, as
suggested in previous studies [7,8,51,59,60], but also via activation of
the IGF-IIR [9,40]. When we inhibited the IGF-IR, IGF-II-mediated
increase in the MMP was not abolished, but the effect of IGF-II on the
MMP completely reverted to the levels of CORT treatment alone when
both IGFRs were inhibited, stressing the inﬂuence of the IGF-IIR on the
MMP. We also detected a decrease in COX activity in the CORT-treated
cells, while IGF-II restored COX activity to the levels of the CO cells,
in agreement with a previous study by our group [9,40]. The effects of
IGF-II on COX activity displayed a peculiar pattern of interaction that
requires further examination to be clariﬁed.
Excessive amounts of ROS andmitochondrial dysfunction are among
the major mechanisms that trigger neurodegeneration [61]; in fact, we
detected a large increase in the ﬂuorescence intensity of FJ, a neurode-
generation marker, in cells incubated in CORT after an additional recov-
ery period of 24 h post-treatment. Once again, IGF-II decreased the FJ
ﬂuorescence intensity, and patterns of the effect of IGF-II on FJ staining
and ROS production were very similar, indicating a relationship be-
tween the antioxidant effect of IGF-II via inhibition of ROS production
and neurodegeneration. However, these ﬁndings do not exclude the
possibility that IGF-II could produce an increase in the activity of the
endosomal–lysosomal system to degrade abnormal intracellular pro-
teins induced by ROS [62–64].
Although many biological effects of IGF-II are mediated by the IGF-
IR, and classically, the IGF-IIR receptor is considered to act as a “clear-
ance receptor” to stabilise the local IGF-II concentration, presently,
there is evidence strongly suggesting that the IGF-IIR is involved in
some of the IGF-II-mediated biological actions [1,6,65]. Interestingly,
in our experiments, the neuroprotective antioxidant effects of IGF-II incortical neurons were also mediated via the IGF-IIR. The individual
blockade of the IGF-IR or the IGF-IIR using speciﬁc inhibitors (JB1
or AB, respectively) did not abolish the IGF-II protective effect,
demonstrating that both the IGF-IR and the IGF-IIR contribute to the an-
tioxidant properties of IGF-II. When both IGFRs were blocked simulta-
neously, the antioxidant effect of IGF-II was completely abolished,
emphasising that both receptors are responsible for the antioxidant
properties of IGF-II. These results strongly support the well-known
antioxidant role of the IGF-IR [66–68]. However, these results also
demonstrate for the ﬁrst time a strong involvement of the IGF-IIR in
these effects. Although IGF-II can also interact with insulin receptor at
a very low afﬁnity, these receptors are expressed at very low levels in
adult neuronal tissue [42,69]. Furthermore, if some of the antioxidant
effects detected in our experiments were due to an interaction between
IGF-II and insulin receptors, these effects should bemaintained after the
blockade of both IGFRs, but this was not the case in our experimental
model.
The speciﬁc signalling pathway associated with the activation of the
IGF-IIR remains largely unclear at present. The actions of the IGF-IIR
could be mediated by G-protein activation calcium modulation [65],
GSK3 [6], MAP kinase [70] and PKC activation [54,65]. Recently, it has
been demonstrated that some of the effects of CORT on neurons areme-
diated by PKC phosphorylation [36,71], suggesting that both IGF-II and
CORT may share a common intracellular pathway involving PKC. In
agreement with the above ﬁndings, in our study, CORT and oxidative
stress activate PKC, as reported by others [36,49,50], and IGF-II treat-
ment restores the levels of PKC to those of the CO cells. However, clari-
ﬁcation of the speciﬁc contribution of this PKC-mediated mechanism
will require further studies.
Experimental evidence demonstrated that mitochondria are
the major source of physiological and pathological cellular ROS and
contribute to the oxidative damage found in several neuropathological
disorders associated with enhanced glucocorticoid levels in tissues.
Furthermore, it has been reported that an increase in glucocorticoid
levels induces oxidative stress [12,14,72] and affects mitochondrial
function, including decreased MMP, increased cell vulnerability, induc-
tion of apoptosis and impaired neuronal plasticity and neurogenesis
[12,13,31,73]. All of these cellular abnormalities could contribute to
the development of neuropsychiatric and neurodegenerative disorders
associated with stress [15,74]. Moreover, these results may explain the
ﬁnding that increased IGF-II expression serves as a defence mechanism
in pathological conditions associated with an elevated CORT concentra-
tion, such as depression [20]. Moreover, the mitochondrial antioxidant
properties of IGF-II could likewise explain the neuroprotective effect
of IGF-II treatment in neuropsychiatric diseases [17,19].
The presence of the antioxidant effect of IGF-II could explain re-
sponses of nervous system tissue to IGF-II under oxidative damage, in
which an increase in the levels of IGF-II were detected under pathologic
conditions, such as ischemia, hypoxia [52,75], amyotrophic lateral scle-
rosis [76,77] and traumatic brain injury [78], in an attempt to counteract
the increase in oxidative damage found in these diseases. In agreement
with these ﬁndings, we recently detected an antioxidant effect of IGF-II
treatment on the brains of aged rats [9]. Moreover, it has been recently
determined that mitochondrial dysfunction and high levels of intracel-
lular ROS could trigger neurodegeneration. The neuroprotective effect
of IGF-II, based in its aforementioned antioxidant properties, could sup-
port the ﬁnding of increased levels of IGF-II in neurodegenerative dis-
eases, such as Alzheimer and Parkinson disease [15,79,80]. In addition,
Dore et al. found that IGF-II alleviated the mitochondrial neurotoxicity
of β-amyloid and indicated that the activation of the IGF-IR was respon-
sible for this effect [39]. They were unable to determine the role of the
IGF-IIR because they did not use any antagonists or inhibitors of IGFR-I
or -II in that study. However, these ﬁndings do not exclude the possibil-
ity that IGF-II could induce increased activity of the endosomal–
lysosomal system (mediated via the IGF-IIR) to degrade abnormal
intracellular proteins induced by ROS [62–64].
1050 E. Martin-Montañez et al. / Biochimica et Biophysica Acta 1842 (2014) 1041–1051In summary, IGF-II could also act as an antioxidant [9,81] to alter the
mechanisms of neuroprotection [42] and neurogenesis [17,41] and,
ultimately, contribute to neuronal plasticity [6,82,83], especially under
conditions in which cognitive deﬁcits are associated with pathologies
or disorders involving imbalanced redox homeostasis, such as aging,
stroke, Alzheimer disease and other neuropsychiatric diseases [84].
5. Conclusion
Based on our analysis of the antioxidant and neuroprotective effects
of IGF-II, a tentative explanation can be offered. After an oxidative insult,
IGF-II acts through IGFRs (both the IGF-IR and the IGF-IIR) to promote
an improvement in mitochondrial function, increasing the levels of
MnSOD and COX activity and the MMP. The recovery of mitochondrial
function may restore the redox status and calcium turnover, thus
decreasing ROS production, membrane lipid peroxidation (primarily
thephospholipid cardiolipin), cytochrome c release, apoptosis, neuronal
damage and neurodegeneration. These results open the ﬁeld to new
pharmacological approaches to treat neuropsychiatric and neurodegen-
erative diseases.
Acknowledgements
We thank Dr. Inma Castilla-Cortazar and Drs. Jesús Hernández
Cabrero and José A Sacristán from Lilly Laboratories (Ref: 8.06/24.1421
and 8.06/241766) (Madrid, Spain) for providing research grants and
the recombinant IGF-II used in this study.
References
[1] J. O'Kusky, P. Ye, Neurodevelopmental effects of insulin-like growth factor signaling,
Front. Neuroendocrinol. 33 (2012) 230–251.
[2] J.M. Holly, C.M. Perks, Insulin-like growth factor physiology: what we have learned
from human studies, Endocrinol. Metab. Clin. North Am. 41 (2012) 249–263 v.
[3] D. LeRoith, V.M. Kavsan, A.P. Koval, C.T. Roberts Jr., Phylogeny of the insulin-like
growth factors (IGFs) and receptors: a molecular approach, Mol. Reprod. Dev. 35
(1993) 332–336 (discussion 337–338).
[4] H. Marquardt, G.J. Todaro, L.E. Henderson, S. Oroszlan, Puriﬁcation and primary
structure of a polypeptide with multiplication-stimulating activity from rat liver
cell cultures. Homology with human insulin-like growth factor II, J. Biol. Chem.
256 (1981) 6859–6865.
[5] R.C. Agis-Balboa, A. Fischer, Generating new neurons to circumvent your fears: the
role of IGF signaling, Cell. Mol. Life Sci. 71 (2014) 21–42.
[6] D.Y. Chen, S.A. Stern, A. Garcia-Osta, B. Saunier-Rebori, G. Pollonini, D. Bambah-
Mukku, R.D. Blitzer, C.M. Alberini, A critical role for IGF-II in memory consolidation
and enhancement, Nature 469 (2011) 491–497.
[7] M.P. Mattson, B. Cheng, V.L. Smith-Swintosky, Mechanisms of neurotrophic factor
protection against calcium- and free radical-mediated excitotoxic injury: implica-
tions for treating neurodegenerative disorders, Exp. Neurol. 124 (1993) 89–95.
[8] M.P. Mattson, Y. Zhang, S. Bose, Growth factors prevent mitochondrial dysfunction,
loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal
neurons deprived of glucose, Exp. Neurol. 121 (1993) 1–13.
[9] I. Castilla-Cortazar, M. Garcia-Fernandez, G. Delgado, J.E. Puche, I. Sierra, R. Barhoum,
S. Gonzalez-Baron, Hepatoprotection and neuroprotection induced by low doses of
IGF-II in aging rats, J. Transl. Med. 9 (2011) 103.
[10] W. Nie, Z.Y. Zhang, J.H. Zhou, Correlation between mitochondrial membrane poten-
tial and neurotoxic effect of corticosterone on primary cultured hippocampal cells,
Sheng Li Xue Bao 53 (2001) 469–472.
[11] L. Zhang, R. Zhou, X. Li, R.J. Ursano, H. Li, Stress-induced change of mitochondria
membrane potential regulated by genomic and non-genomic GR signaling: a possi-
ble mechanism for hippocampus atrophy in PTSD, Med. Hypotheses 66 (2006)
1205–1208.
[12] W. Liu, C. Zhou, Corticosterone reduces brain mitochondrial function and expression
of mitofusin, BDNF in depression-like rodents regardless of exercise precondition-
ing, Psychoneuroendocrinology 37 (2012) 1057–1070.
[13] J. Du, Y. Wang, R. Hunter, Y. Wei, R. Blumenthal, C. Falke, R. Khairova, R. Zhou, P.
Yuan, R. Machado-Vieira, B.S. McEwen, H.K. Manji, Dynamic regulation of mitochon-
drial function by glucocorticoids, Proc. Natl. Acad. Sci. 106 (2009) 3543–3548.
[14] A. Zaﬁr, N. Banu, Modulation of in vivo oxidative status by exogenous corticosterone
and restraint stress in rats, Stress 12 (2009) 167–177.
[15] K.-W. Lee, J.-B. Kim, J.-S. Seo, T.-K. Kim, J.-Y. Im, I.-S. Baek, K.-S. Kim, J.-K. Lee, P.-L.
Han, Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice
via generation of metabolic oxidative stress, J. Neurochem. 108 (2009) 165–175.
[16] G.T. Rezin, G. Amboni, A.I. Zugno, J. Quevedo, E.L. Streck, Mitochondrial dysfunction
and psychiatric disorders, Neurochem. Res. 34 (2009) 1021–1029.[17] Y. Ouchi, Y. Banno, Y. Shimizu, S. Ando, H. Hasegawa, K. Adachi, T. Iwamoto, Reduced
adult hippocampal neurogenesis and working memory deﬁcits in the Dgcr8-
deﬁcient mouse model of 22q11.2 deletion-associated schizophrenia can be rescued
by IGF2, J. Neurosci. 33 (2013) 9408–9419.
[18] B.M. Andrus, K. Blizinsky, P.T. Vedell, K. Dennis, P.K. Shukla, D.J. Schaffer, J. Radulovic,
G.A. Churchill, E.E. Redei, Gene expression patterns in the hippocampus and amyg-
dala of endogenous depression and chronic stress models, Mol. Psychiatry 17
(2012) 49–61.
[19] B.H. Cline, H.W.M. Steinbusch, D. Malin, A.V. Revishchin, G.V. Pavlova, R. Cespuglio,
T. Strekalova, The neuronal insulin sensitizer dicholine succinate reduces stress-
induced depressive traits and memory deﬁcit: possible role of insulin-like growth
factor 2, BMC Neurosci. 13 (2012) 110.
[20] P. Lisowski, G.R. Juszczak, J. Goscik, A.M. Stankiewicz, M. Wieczorek, L.
Zwierzchowski, A.H. Swiergiel, Stress susceptibility-speciﬁc phenotype associated
with different hippocampal transcriptomic responses to chronic tricyclic antide-
pressant treatment in mice, BMC Neurosci. 14 (2013) 144.
[21] G.J. Brewer, Isolation and culture of adult rat hippocampal neurons, J. Neurosci.
Methods 71 (1997) 143–155.
[22] S. Jung, Y. Lee, G. Kim, H. Son, D.H. Lee, G.S. Roh, S.S. Kang, G.J. Cho, W.S. Choi, H.J.
Kim, Decreased expression of extracellular matrix proteins and trophic factors in
the amygdala complex of depressed mice after chronic immobilization stress, BMC
Neurosci. 13 (2012) 58.
[23] R. Sapolsky, S. Brooke, B. Stein-Behrens, Methodologic issues in studying
glucocorticoid-induced damage to neurons, J. Neurosci. Methods 58 (1995) 1–15.
[24] J.Y. Koh, D.W. Choi, Quantitative determination of glutamate mediated cortical neu-
ronal injury in cell culture by lactate dehydrogenase efﬂux assay, J. Neurosci.
Methods 20 (1987) 83–90.
[25] I. Pasquali-Ronchetti, M.I. Garcia-Fernandez, F. Boraldi, D. Quaglino, D. Gheduzzi, C.
De Vincenzi Paolinelli, R. Tiozzo, S. Bergamini, D. Ceccarelli, U. Muscatello, Oxidative
stress in ﬁbroblasts from patients with pseudoxanthoma elasticum: possible role in
the pathogenesis of clinical manifestations, J. Pathol. 208 (2006) 54–61.
[26] J. Luo, N. Li, J. Paul Robinson, R. Shi, Detection of reactive oxygen species by ﬂow cy-
tometry after spinal cord injury, J. Neurosci. Methods 120 (2002) 105–112.
[27] A.W. Girotti, Lipid hydroperoxide generation, turnover, and effector action in biolog-
ical systems, J. Lipid Res. 39 (1998) 1529–1542.
[28] K. Arab, J.P. Steghens, Plasma lipid hydroperoxides measurement by an automated
xylenol orange method, Anal. Biochem. 325 (2004) 158–163.
[29] F. Boraldi, M. Garcia-Fernandez, C. Paolinelli-Devincenzi, G. Annovi, L. Schurgers, C.
Vermeer, P. Cianciulli, I. Ronchetti, D. Quaglino, Ectopic calciﬁcation in beta-
thalassemia patients is associated with increased oxidative stress and lower MGP
carboxylation, Biochim. Biophys. Acta 1832 (2013) 2077–2084.
[30] M.I. Garcia-Fernandez, D. Gheduzzi, F. Boraldi, C.D. Paolinelli, P. Sanchez, P.
Valdivielso, M.J. Morilla, D. Quaglino, D. Guerra, S. Casolari, L. Bercovitch, I.
Pasquali-Ronchetti, Parameters of oxidative stress are present in the circulation of
PXE patients, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1782 (2008) 474–481.
[31] M. Garcia-Fernandez, I. Castilla-Cortazar, M. Diaz-Sanchez, F. Diez Caballero, A.
Castilla, A. Diaz Casares, I. Varela-Nieto, S. Gonzalez-Baron, Effect of IGF-I on total
serum antioxidant status in cirrhotic rats, J. Physiol. Biochem. 59 (2003) 145–146.
[32] L. Eide, C.T. McMurray, Culture of adult mouse neurons, Biotechniques 38 (2005)
99–104.
[33] H. Lecoeur, D. Chauvier, A. Langonne, D. Rebouillat, B. Brugg, J. Mariani, L. Edelman,
E. Jacotot, Dynamic analysis of apoptosis in primary cortical neurons by ﬁxed- and
real-time cytoﬂuorometry, Apoptosis 9 (2004) 157–169.
[34] M. García-Fernández, E. Castilla-Ortega, C. Pedraza, E. Blanco, I. Hurtado-Guerrero,
M.A. Barbancho, J. Chun, F. Rodríguez-de-Fonseca, G. Estivill-Torrús, L.J.S. Núñez,
Chronic immobilization in the malpar1 knockout mice increases oxidative stress
in the hippocampus, Int. J. Neurosci. 122 (2012) 583–589.
[35] G. Schmuck, R. Kahl, The use of Fluoro-Jade in primary neuronal cell cultures, Arch.
Toxicol. 83 (2009) 397–403.
[36] M. Yoshiya, Y. Komatsuzaki, Y. Hojo, M. Ikeda, H. Mukai, Y. Hatanaka, G. Murakami,
M. Kawata, T. Kimoto, S. Kawato, Corticosterone rapidly increases thorns of CA3
neurons via synaptic/extranuclear glucocorticoid receptor in rat hippocampus,
Front. Neural Circ. 7 (2013) 191.
[37] S. Sato, H. Osanai, T. Monma, T. Harada, A. Hirano, M. Saito, S. Kawato, Acute effect of
corticosterone on N-methyl-D-aspartate receptor-mediated Ca2+ elevation in
mouse hippocampal slices, Biochem. Biophys. Res. Commun. 321 (2004) 510–513.
[38] Y. Xu, C. Zhang, R. Wang, S.S. Govindarajan, P.A. Barish, M.M. Vernon, C. Fu, A.P.
Acharya, L. Chen, E. Boykin, J. Yu, J. Pan, J.M. O'Donnell, W.O. Ogle, Corticosterone
induced morphological changes of hippocampal and amygdaloid cell lines are
dependent on 5-HT7 receptor related signal pathway, Neuroscience 182 (2011)
71–81.
[39] S. Dore, S. Kar, R. Quirion, Insulin-like growth factor I protects and rescues hippo-
campal neurons against beta-amyloid- and human amylin-induced toxicity, Proc.
Natl. Acad. Sci. U. S. A. 94 (1997) 4772–4777.
[40] M. Garcia-Fernandez, I. Sierra, J.E. Puche, L. Guerra, I. Castilla-Cortazar, Liver mito-
chondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging
rats, J. Transl. Med. 9 (2011) 123.
[41] O. Bracko, T. Singer, S. Aigner, M. Knobloch, B. Winner, J. Ray, G.D. Clemenson, H.
Suh, S. Couillard-Despres, L. Aigner, F.H. Gage, S. Jessberger, Gene expression proﬁl-
ing of neural stem cells and their neuronal progeny reveals IGF2 as a regulator of
adult hippocampal neurogenesis, J. Neurosci. 32 (2012) 3376–3387.
[42] B. Cheng, M.P. Mattson, IGF-I and IGF-II protect cultured hippocampal and septal
neurons against calcium-mediated hypoglycemic damage, J. Neurosci. 12 (1992)
1558–1566.
[43] H.J. Walter, M. Berry, D.J. Hill, S. Cwyfan-Hughes, J.M. Holly, A. Logan, Distinct sites of
insulin-like growth factor (IGF)-II expression and localization in lesioned rat brain:
1051E. Martin-Montañez et al. / Biochimica et Biophysica Acta 1842 (2014) 1041–1051possible roles of IGF binding proteins (IGFBPs) in the mediation of IGF-II activity,
Endocrinology 140 (1999) 520–532.
[44] S.P. Nissley, M.M. Rechler, Somatomedin/insulin-like growth factor tissue receptors,
Clin. Endocrinol. Metab. 13 (1984) 43–67.
[45] J.C. Chavez, J.C. LaManna, Activation of hypoxia-inducible factor-1 in the rat cerebral
cortex after transient global ischemia: potential role of insulin-like growth factor-1,
J. Neurosci. 22 (2002) 8922–8931.
[46] R. Brigelius-Flohé, M. Maiorino, Glutathione peroxidases, Biochim. Biophys. Acta
Gen. Subj. 1830 (2013) 3289–3303.
[47] T. Iijima, Mitochondrial membrane potential and ischemic neuronal death, Neurosci.
Res. 55 (2006) 234–243.
[48] S. Arnold, Cytochrome c oxidase and its role in neurodegeneration and neuroprotec-
tion, Adv. Exp. Med. Biol. 748 (2012) 305–339.
[49] D. Cosentino-Gomes, N. Rocco-Machado, J.R. Meyer-Fernandes, Cell signaling through
protein kinase C oxidation and activation, Int. J. Mol. Sci. 13 (2012) 10697–10721.
[50] R. Gopalakrishna, S. Jaken, Protein kinase C signaling and oxidative stress, Free
Radic. Biol. Med. 28 (2000) 1349–1361.
[51] M. Garcia-Fernandez, G. Delgado, J.E. Puche, S. Gonzalez-Baron, I. Castilla
Cortazar, Low doses of insulin-like growth factor I improve insulin resistance,
lipid metabolism, and oxidative damage in aging rats, Endocrinology 149
(2008) 2433–2442.
[52] P. Boksa, Y. Zhang, A. Amritraj, S. Kar, Birth insults involving hypoxia produce long-
term increases in hippocampal [125I]insulin-like growth factor-I and -II receptor
binding in the rat, Neuroscience 139 (2006) 451–462.
[53] K.B. Mackay, S.A. Loddick, G.S. Naeve, A.M. Vana, G.M. Verge, A.C. Foster, Neuropro-
tective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro
and in vivo, J. Cereb. Blood Flow Metab. 23 (2003) 1160–1167.
[54] L.K. Harris, M. Westwood, Biology and signiﬁcance of signalling pathways activated
by IGF-II, Growth Factors 30 (2012) 1–12.
[55] I. Fridovich, Mitochondria: are they the seat of senescence? Aging Cell 3 (2004)
13–16.
[56] J. Friedman, The role of free radicals in the nervous system, in: N.G.a.H.H. Gobel (Ed.),
Oxidative Stress and Free Radical Damage in Neurology, vol. VIII, Humana Press, c/o
Springer Science + Business Media, New York, 2011, pp. 1–17.
[57] S.-R. Lee, H.-K. Kim, I.-S. Song, J. Youm, L.A. Dizon, S.-H. Jeong, T.-H. Ko, H.-J. Heo, K.S.
Ko, B.D. Rhee, N. Kim, J. Han, Glucocorticoids and their receptors: insights into
speciﬁc roles in mitochondria, Prog. Biophys. Mol. Biol. 112 (2013) 44–54.
[58] S.A. Detmer, D.C. Chan, Functions and dysfunctions of mitochondrial dynamics, Nat.
Rev. Mol. Cell Biol. 8 (2007) 870–879.
[59] R. Perez, M. Garcia-Fernandez, M. Diaz-Sanchez, J.E. Puche, G. Delgado, M. Conchillo,
J. Muntane, I. Castilla-Cortazar, Mitochondrial protection by low doses of insulin-like
growth factor-I in experimental cirrhosis, World J. Gastroenterol. 14 (2008)
2731–2739.
[60] J.E. Puche, M. Garcia-Fernandez, J. Muntane, J. Rioja, S. Gonzalez-Baron, I. Castilla
Cortazar, Low doses of insulin-like growth factor-I induce mitochondrial protection
in aging rats, Endocrinology 149 (2008) 2620–2627.
[61] X. Wang, E.K. Michaelis, Selective neuronal vulnerability to oxidative stress in the
brain, Front. Aging Neurosci. 2 (2010) 12.
[62] A. Amritraj, C. Hawkes, A.L. Phinney, H.T. Mount, C.D. Scott, D. Westaway, S. Kar,
Altered levels and distribution of IGF-II/M6P receptor and lysosomal enzymes in
mutant APP and APP + PS1 transgenic mouse brains, Neurobiol. Aging 30 (2009)
54–70.
[63] C. Hawkes, A. Amritraj, R.G. Macdonald, J.H. Jhamandas, S. Kar, Heterotrimeric
G proteins and the single-transmembrane domain IGF-II/M6P receptor:
functional interaction and relevance to cell signaling, Mol. Neurobiol. 35 (2007)
329–345.
[64] V.C. Russo, P.D. Gluckman, E.L. Feldman, G.A.Werther, The insulin-like growth factor
system and its pleiotropic functions in brain, Endocr. Rev. 26 (2005) 916–943.
[65] C. Hawkes, J.H. Jhamandas, K.H. Harris, W. Fu, R.G. MacDonald, S. Kar, Single trans-
membrane domain insulin-like growth factor-II/mannose-6-phosphate receptorregulates central cholinergic function by activating a G-protein-sensitive, protein ki-
nase C-dependent pathway, J. Neurosci. 26 (2006) 585–596.
[66] D. Davila, I. Torres-Aleman, Neuronal death by oxidative stress involves activation of
FOXO3 through a two-arm pathway that activates stress kinases and attenuates
insulin-like growth factor I signaling, Mol. Biol. Cell 19 (2008) 2014–2025.
[67] M. Garcia-Fernandez, I. Castilla-Cortazar, M. Diaz-Sanchez, I. Navarro, J.E. Puche, A.
Castilla, A.D. Casares, E. Clavijo, S. Gonzalez-Baron, Antioxidant effects of insulin-
like growth factor-I (IGF-I) in rats with advanced liver cirrhosis, BMC Gastroenterol.
5 (2005) 7.
[68] J.E. Puche, I. Castilla-Cortazar, Human conditions of insulin-like growth factor-I (IGF-I)
deﬁciency, J. Transl. Med. 10 (2012) 224.
[69] S.L. Chiu, H.T. Cline, Insulin receptor signaling in the development of neuronal struc-
ture and function, Neural Dev. 5 (2010) 7.
[70] T. McKinnon, C. Chakraborty, L.M. Gleeson, P. Chidiac, P.K. Lala, Stimulation
of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2
receptor involving inhibitory G protein(s) and phosphorylation of MAPK, J. Clin.
Endocrinol. Metab. 86 (2001) 3665–3674.
[71] Y. Zhang, H. Sheng, J. Qi, B. Ma, J. Sun, S. Li, X. Ni, Glucocorticoid acts on a putative G
protein-coupled receptor to rapidly regulate the activity of NMDA receptors in
hippocampal neurons, Am. J. Physiol. Endocrinol. Metab. 302 (2012) E747–E758.
[72] B.G. Pérez-Nievas, B. García-Bueno, J.R. Caso, L. Menchén, J.C. Leza, Corticosterone
as a marker of susceptibility to oxidative/nitrosative cerebral damage after stress
exposure in rats, Psychoneuroendocrinology 32 (2007) 703–711.
[73] A. Cheng, Y. Hou, M.P. Mattson, Mitochondria and neuroplasticity, ASN Neurol. 2
(2010) e00045.
[74] C. Hoschl, T. Hajek, Hippocampal damage mediated by corticosteroids—a neuropsy-
chiatric research challenge, Eur. Arch. Psychiatry Clin. Neurosci. 251 (Suppl. 2)
(2001) II81–II88.
[75] W.H. Lee, J.A. Clemens, C.A. Bondy, Insulin-like growth factors in the response to
cerebral ischemia, Mol. Cell. Neurosci. 3 (1992) 36–43.
[76] B. Liu, H. Zhang, C. Xu, G. Yang, J. Tao, J. Huang, J. Wu, X. Duan, Y. Cao, J. Dong,
Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary
cultured rat hippocampal neurons, Brain Res. 1375 (2011) 59–67.
[77] S.F. Sorrells, J.R. Caso, C.D. Munhoz, R.M. Sapolsky, The stressed CNS: when glucocor-
ticoids aggravate inﬂammation, Neuron 64 (2009) 33–39.
[78] M. Giannakopoulou, M. Mansour, E. Kazanis, E. Bozas, H. Philpipidis, F.
Stylianopoulou, NMDA receptor mediated changes in IGF-II gene expression in the
rat brain after injury and the possible role of nitric oxide, Neuropathol. Appl.
Neurobiol. 26 (2000) 513–521.
[79] S. Kar, J. Poirier, J. Guevara, D. Dea, C. Hawkes, Y. Robitaille, R. Quirion, Cellular
distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in
normal human brain and its alteration in Alzheimer's disease pathology, Neurobiol.
Aging 27 (2006) 199–210.
[80] M. Tong, M. Dong, S.M. de la Monte, Brain insulin-like growth factor and
neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies:
potential role of manganese neurotoxicity, J. Alzheimers Dis. 16 (2009) 585–599.
[81] X. Wang, L.P. Wang, H. Tang, W.Y. Shan, D. Liu, Y.Y. Wu, Q. Tian, J.Z. Wang, L.Q. Zhu,
Acetyl-l-carnitine rescues scopolamine-induced memory deﬁcits by restoring insu-
lin-like growth factor II via decreasing p53 oxidation, Neuropharmacology 76
(2014) 80–87.
[82] A. Amritraj, G. Rauw, G.B. Baker, S. Kar, Leu27 insulin-like growth factor-II, an
insulin-like growth factor-II analog, attenuates depolarization-evoked GABA release
from adult rat hippocampal and cortical slices, Neuroscience 170 (2010) 722–730.
[83] M.J. Schmeisser, B. Baumann, S. Johannsen, G.F. Vindedal, V. Jensen, O.C. Hvalby, R.
Sprengel, J. Seither, A. Maqbool, A. Magnutzki, M. Lattke, F. Oswald, T.M. Boeckers,
T. Wirth, IkappaB kinase/nuclear factor kappaB-dependent insulin-like growth fac-
tor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2
receptor signaling, J. Neurosci. 32 (2012) 5688–5703.
[84] E.E. Benarroch, Insulin-like growth factors in the brain and their potential clinical
implications, Neurology 79 (2012) 2148–2153.
